Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

January 16, 2018

Study Completion Date

August 3, 2022

Conditions
Breast CancerOvarian NeoplasmPain
Interventions
DIETARY_SUPPLEMENT

Omega-3 fatty acid

"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."

DIETARY_SUPPLEMENT

Placebo

"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"

DRUG

Paclitaxel

Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.

Trial Locations (2)

87106

University of New Mexico Comprehensive Cancer Center, Albuquerque

87110

Presbyterian Medical Group, Albuquerque

All Listed Sponsors
collaborator

Alliance Healthcare Foundation

OTHER

lead

New Mexico Cancer Research Alliance

OTHER

NCT01821833 - Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel | Biotech Hunter | Biotech Hunter